Kventiax

Quetiapine, the active ingredient in Kventiax, is an atypical antipsychotic presented as an oral formulation for oral use. It is used to treat schizophrenia, bipolar disorder and as adjunct therapy for major depressive disorder in adult patients.

GNH USA supplies Kventiax as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Quetiapine is employed in the management of several psychiatric disorders.

Schizophrenia: reduces psychotic symptoms and improves functional outcomes. Bipolar disorder (manic and depressive episodes): stabilises mood and mitigates manic or depressive episodes. Major depressive disorder (adjunct therapy): enhances antidepressant response when added to standard treatment.

Quetiapine may cause a range of adverse reactions.

Common Side Effects: - Drowsiness or sedation - Dry mouth - Constipation - Weight gain - Dizziness - Increased appetite

Serious or Rare Side Effects: - Orthostatic hypotension - Neuroleptic malignant syndrome - Tardive dyskinesia - Suicidal thoughts or behaviours - Severe allergic reactions (e.g., rash, angioedema) - Elevated blood glucose or new‑onset diabetes

When prescribing quetiapine, several safety considerations are recommended.

Monitor blood pressure: watch for orthostatic hypotension, especially during dose initiation. Assess metabolic parameters: regularly check weight, fasting glucose and lipid profile. Evaluate for suicidal ideation: particularly in early treatment phases and in younger adults. Review hepatic function: adjust dosing in patients with significant liver impairment. Store at ambient temperature: keep below 25 °C in the original packaging, protect from moisture.

Quetiapine can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may markedly increase quetiapine plasma concentrations. - Concurrent CNS depressants (e.g., benzodiazepines, alcohol): risk of excessive sedation and respiratory depression. - QT‑prolonging agents (e.g., certain antiarrhythmics, fluoroquinolones): may increase the risk of cardiac arrhythmias.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce therapeutic levels. - Antihypertensive drugs: additive hypotensive effect may require dose adjustment. - Anticholinergic medications: combined use can heighten anticholinergic burden and cognitive effects.